11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Activation of the Phosphoinositide-3-Kinase and Mammalian Target of Rapamycin Signaling Pathways Are Associated With Shortened Survival in Patients With Malignant Peritoneal Mesothelioma

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          BACKGROUND:

          Malignant peritoneal mesothelioma (MPM) is a rare malignancy of the serosal membranes of the abdominal cavity. This cancer is ultimately fatal in almost all afflicted individuals; however, there is marked variability in its clinical behavior: Some patients die rapidly, and others survive for many years. In the current study, the authors investigated the molecular nature of MPM to obtain insights into the heterogeneity of its clinical behavior and to identify new therapeutic targets for intervention.

          METHODS:

          Fresh pretreatment tumor samples were collected from 41 patients with MPM who underwent surgical cytoreduction and received regional intraoperative chemotherapy perfusion. From those samples, gene expression analyses were performed. The major cellular pathways that were identified in this cancer were inhibited using a pathway-specific inhibitor.

          RESULTS:

          Unsupervised clustering of genes identified 2 distinct groups of patients with significantly different survivals (Group A: median survival, 24 months; Group B: median survival, 69.5 months; P = .035). Phosphoinositide-3-kinase (PI3K) and the closely interacting mammalian target of rapamycin (mTOR) signaling pathways were overexpressed predominantly in the poor survival group; and the genes of these pathways, phosphoinositide-3-kinase, catalytic, α polypeptide (PIK3CA) and rapamycin-insensitive companion of mammalian target of rapamycin (RICTOR), were highly significantly predictive of shortened patient survival in Group A. The role of these pathways in MPM tumor progression was also investigated by treating 2 MPM cell lines with BEZ235, a dual-class PI3K and mTOR inhibitor, and the authors observed significant inhibition of downstream cell signaling and cell proliferation.

          CONCLUSIONS:

          Taken together, the results from this study revealed that, based on gene expression profiles, there were 2 distinct patient groups with significantly different survival and that targeting the PI3K and mTOR signaling pathways may have significant therapeutic value in patients with MPM.

          Related collections

          Author and article information

          Journal
          0374236
          2771
          Cancer
          Cancer
          Cancer
          0008-543X
          1097-0142
          11 January 2020
          13 September 2010
          15 January 2011
          31 January 2020
          : 117
          : 2
          : 361-371
          Affiliations
          [1 ]Division of Surgical Oncology, Department of Surgery, The University of Maryland School of Medicine, Baltimore, Maryland;
          [2 ]The Marlene and Stewart Greenebaum Cancer Center, The University of Maryland School of Medicine, Baltimore, Maryland;
          [3 ]Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland;
          [4 ]Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
          Author notes

          Dr. David L. Bartlett’ and Dr. James F. Pingpank’s current address: Department of Surgery, Division of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

          Dr. Steven K. Libutti’s current address: Department of Surgery, Montefiore Medical Center, Bronx, New York.

          Corresponding author: H. Richard Alexander, Jr., MD, Department of Surgery, University of Maryland School of Medicine, 22 South Greene Street S4B05A, Baltimore, MD 21201; Fax: (410) 328-5919; hralexander@ 123456smail.umaryland.edu
          Article
          PMC6993181 PMC6993181 6993181 nihpa1066299
          10.1002/cncr.25555
          6993181
          20839315
          e876f365-fdf5-4aec-9bc1-7f9a4118b837
          History
          Categories
          Article

          patient survival,microarray,cancer pathways,peritoneal mesothelioma

          Comments

          Comment on this article